Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $743.4 million.

  • Neurocrine Biosciences' Total Current Liabilities rose 4642.51% to $743.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $743.4 million, marking a year-over-year increase of 4642.51%. This contributed to the annual value of $743.4 million for FY2025, which is 4642.51% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Total Current Liabilities is $743.4 million, which was up 4642.51% from $638.0 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Total Current Liabilities peaked at $743.4 million during Q4 2025, and registered a low of $190.0 million during Q1 2021.
  • Moreover, its 4-year median value for Total Current Liabilities was $522.9 million (2025), whereas its average is $495.4 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Total Current Liabilities plummeted by 6302.78% in 2021, and later surged by 9056.4% in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Total Current Liabilities stood at $225.9 million in 2021, then soared by 189.86% to $654.8 million in 2023, then fell by 22.46% to $507.7 million in 2024, then soared by 46.43% to $743.4 million in 2025.
  • Its Total Current Liabilities was $743.4 million in Q4 2025, compared to $638.0 million in Q3 2025 and $546.3 million in Q2 2025.